A	B	C
1	Main
2		Brand Name	BIM-51077
3		Generic Name	taspoglutide
4		Mechanism	Human GLP-1.
5		Economics	Ipsen
6		Administration	29 gauge vs 23 gauge for exenatide LAR and less viscous solution than LAR. Once-weekly dosing.
7		Competition	exenatide LAR
8		Clinical Trials
9			Phase III - "T-EMERGE-2" to begin in 2H 2008 - NDA to be filed in 2010 - Results press released 10/29/2009 n=1189
10			Taspo 10mg once weekly versus Exenatide 10mcg twice daily
11			Superior A1C control.
12
13			Phase II - ADA 2008 presentation
14			n=306 vs placebo for 8 weeks.
15			59%, 79%, 81% response rate across qw doses. 44% and 63% across biw dosing. 17% for placebo.